Abstract 96P
Background
Alveolar soft part sarcoma is a rare malignant tumor of unknown genetic predisposition and unpredicted clinical picture. There are few studies on this rare type of sarcoma due to its scarcity which lead to under-developed guidelines for its screening and treatment. So, this study aims to add more evidence and data about this rare type.
Methods
Data of 243 patients was extracted from the Surveillance, Epidemiological, and End Results (SEER) database diagnosed from 2000-2019. We analyzed Age-Adjusted Trends, Rates are per 100,000 and a standard population of 2000 US std population (19 age groups – census P25-1130). Percent changes were calculated using 1 year for each end point and Age adjusted annual percentage changes were calculated using weighted least squares method. Data was analyzed using SPSS 25. Cox regression model was performed for survival analysis and evaluate many predictors.
Results
The Overall 5-year Survival was 62.2%. The age standardized 3-year and 5-year relative survival was 63% and 43.3%. The age-adjusted trend analysis showed that annual percentage change (APC) was 0.7 (95% CI -0.8 to 2.2) from the year 2000 to 2019 and the percent change (PC) was -21.5. This increase occurred across all ages, races, stages, and grades. Performing cox regression model, Age and Gender were significant predictors for survival (P<0.002) while year of diagnosis and race had no significant impact on survival (P>0.05).
Conclusions
Alveolar soft part sarcoma has good overall relative survival outcome due to early diagnosis and advanced treatment options. Our results gave age and gender more priority than year of diagnosis and race in the prediction of survival outcome. Our results also indicated a slight increase in the number of diagnosed patients each year which make us pay more attention for the screening of this rare type.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.